Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 4:13:950225.
doi: 10.3389/fphar.2022.950225. eCollection 2022.

Fasting plasma glucose and HbA1c levels predict the risk of type 2 diabetes and diabetic retinopathy in a Thai high-risk population with prediabetes

Chaiwat Washirasaksiri  1 , Weerachai Srivanichakorn  1 , Nutsakol Borrisut  1 , Tullaya Sitasuwan  1 , Rungsima Tinmanee  1 , Chayanis Kositamongkol  1 , Pinyapat Ariyakunaphan  1 , Chonticha Auesomwang  1 , Naruemit Sayabovorn  1 , Thanet Chaisathaphol  1 , Pochamana Phisalprapa  1
Affiliations

Fasting plasma glucose and HbA1c levels predict the risk of type 2 diabetes and diabetic retinopathy in a Thai high-risk population with prediabetes

Chaiwat Washirasaksiri et al. Front Pharmacol. .

Abstract

Introduction: The incidences of diabetes and diabetic retinopathy (DR) in Thai high-risk individuals with prediabetes have not been identified. This study compared diabetes and DR incidences among people at risk with different glycemic levels, using fasting plasma glucose (FPG) and hemoglobin A1C (HbA1c). Materials and methods: A historical cohort study estimating risk of type 2 diabetes and DR was conducted among outpatients, using FPG and HbA1c measurements at recruitment and monitored for ≥5 years. High-risk participants (defined as having metabolic syndrome or atherosclerotic cardiovascular disease) were categorized by glycemic level into 4 groups: 1) impaired fasting glucose (IFG)-/HbA1c- (FPG <110 mg/dl; HbA1c < 6.0%); 2) IFG+/HbA1c- (FPG 110-125 mg/dl; HbA1c < 6.0%); 3) IFG-/HbA1c+ (FPG <110 mg/dl; HbA1c 6.0%-6.4%); and 4) IFG+/HbA1c+ (FPG 110-125 mg/dl; HbA1c 6.0%-6.4%). The incidences of type 2 diabetes mellitus (T2DM) and DR were obtained and estimated using Kaplan-Meier analysis. Cox regression models explored hazard ratios (HRs). Results: We recruited 8,977 people at risk (metabolic syndrome, 89.9%; atherosclerotic cardiovascular disease, 16.9%). The baseline cohort consisted of 1) IFG-/HbA1c- (n = 4,221; 47.0%); 2) IFG+/HbA1c- (n = 1,274; 14.2%); 3) IFG-/HbA1c+ (n = 2,151; 24.0%); and 4) IFG+/HbA1c+ (n = 1,331; 14.8%). Their 5-year T2DM incidences were 16.0%, 26.4%, 30.8%, and 48.5% (p < 0.001). The median DR follow-up was 7.8 years (interquartile range, 7.0-8.4 years). The DR incidences were 0.50, 0.63, 1.44, and 2.68/1,000 person-years (p < 0.001) for IFG-/HbA1c-, IFG+/HbA1c-, IFG-/HbA1c+, and IFG+/HbA1c+, respectively. Compared with IFG-/HbA1c-, the multivariable-adjusted HRs (95% CI) for incident diabetes were 1.94 (1.34-2.80), 2.45 (1.83-3.29), and 4.56 (3.39-6.15) for IFG+/HbA1c-, IFG-/HbA1c+, and IFG+/HbA1c+, respectively. As for incident DR, the corresponding HRs were 0.67 (0.08-5.76), 4.74 (1.69-13.31), and 5.46 (1.82-16.39), respectively. Conclusion: The 5-year incidence of T2DM in Thai high-risk participants with prediabetes was very high. The incidences of diabetes and DR significantly increased with higher degrees of dysglycemia. High-risk people with FPG 110-125 mg/dl and HbA1c 6.0%-6.4% were more likely to develop T2DM and DR. Such individuals should receive priority lifestyle and pharmacological management.

Keywords: HbA1c; diabetes incidence; diabetic retinopathy incidence; fasting plasma glucose; high-risk people; prediabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Enrollment of the study subjects.
See this image and copyright information in PMC

References

    1. Alberti K. G., Eckel R. H., Grundy S. M., Zimmet P. Z., Cleeman J. I., Donato K. A., et al. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood Institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120 (16), 1640–1645. 10.1161/CIRCULATIONAHA.109.192644 - DOI - PubMed
    1. Alberti K. G., Zimmet P., Shaw J., Group I. D. F. E. T. F. C. (2005). The metabolic syndrome-a new worldwide definition. Lancet 366 (9491), 1059–1062. 10.1016/S0140-6736(05)67402-8 - DOI - PubMed
    1. Ali M. K., Bullard K. M., Saydah S., Imperatore G., Gregg E. W. (2018). Cardiovascular and renal burdens of prediabetes in the USA: Analysis of data from serial cross-sectional surveys, 1988-2014. Lancet. Diabetes Endocrinol. 6 (5), 392–403. 10.1016/S2213-8587(18)30027-5 - DOI - PMC - PubMed
    1. Aoyama-Sasabe S., Fukushima M., Xin X., Taniguchi A., Nakai Y., Mitsui R., et al. (2016). Insulin secretory defect and insulin resistance in isolated impaired fasting glucose and isolated impaired glucose tolerance. J. Diabetes Res. 2016, 1298601. 10.1155/2016/1298601 - DOI - PMC - PubMed
    1. Aro A., Kauppinen A., Kivinen N., Selander T., Kinnunen K., Tuomilehto J., et al. (2019). Life style intervention improves retinopathy status—the. Finn. Diabetes Prev. Study 11 (7), 1691. - PMC - PubMed